Organogenesis Holdings Inc (NASDAQ:ORGO) Director Alan A. Ades bought 105,100 shares of the company’s stock in a transaction dated Thursday, September 5th. The shares were acquired at an average price of $4.50 per share, for a total transaction of $472,950.00. Following the completion of the transaction, the director now directly owns 67,896,723 shares in the company, valued at $305,535,253.50. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Organogenesis stock traded up $0.76 during midday trading on Friday, reaching $5.40. The company had a trading volume of 667,002 shares, compared to its average volume of 99,193. Organogenesis Holdings Inc has a 12-month low of $3.56 and a 12-month high of $310.90. The business has a fifty day moving average of $4.64. The company has a current ratio of 1.51, a quick ratio of 1.14 and a debt-to-equity ratio of 3.78.

Organogenesis (NASDAQ:ORGO) last issued its quarterly earnings results on Friday, August 9th. The company reported ($0.11) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.02. The company had revenue of $64.95 million during the quarter, compared to analysts’ expectations of $61.00 million. On average, sell-side analysts predict that Organogenesis Holdings Inc will post -0.5 EPS for the current fiscal year.

A number of equities research analysts have recently commented on ORGO shares. Zacks Investment Research cut Organogenesis from a “hold” rating to a “sell” rating in a research report on Saturday, August 31st. BTIG Research set a $12.00 target price on Organogenesis and gave the company a “buy” rating in a research report on Friday, August 9th. Finally, Credit Suisse Group started coverage on Organogenesis in a research report on Monday, August 26th. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $10.80.

A number of institutional investors have recently modified their holdings of ORGO. Citadel Advisors LLC purchased a new position in Organogenesis in the 2nd quarter valued at about $200,000. Bank of New York Mellon Corp purchased a new position in Organogenesis in the 2nd quarter valued at about $210,000. Northern Trust Corp lifted its stake in Organogenesis by 134.3% in the 2nd quarter. Northern Trust Corp now owns 41,066 shares of the company’s stock valued at $312,000 after buying an additional 23,540 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Organogenesis by 36.6% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 86,495 shares of the company’s stock valued at $658,000 after buying an additional 23,180 shares in the last quarter. Finally, Moors & Cabot Inc. purchased a new position in Organogenesis in the 2nd quarter valued at about $694,000. 1.60% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types.

Recommended Story: Can individual investors take part in an IPO?

Receive News & Ratings for Organogenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organogenesis and related companies with MarketBeat.com's FREE daily email newsletter.